— Know what they know.
Not Investment Advice

DAWN NASDAQ

Day One Biopharmaceuticals, Inc.
1W: +0.3% 1M: +0.8% 3M: +80.2% YTD: +143.3% 1Y: +189.4% 3Y: +69.9%
$21.53
Last traded 2026-04-24 — delisted
NASDAQ · Healthcare · Biotechnology · $2.2B mcap · 71M float · 5.62% daily turnover · Short 35% of daily vol

Balance Sheet Trends

Total Assets
$508M -12.9% ▼
5Y CAGR: +61.9%
Total Liabilities
$67M -16.7% ▼
5Y CAGR: +97.8%
Shareholders Equity
$441M -12.3% ▼
5Y CAGR: +63.5%
Cash & Investments
$441M -17.0% ▼
5Y CAGR: +58.8%
Total Debt
$3M +7.3% ▲
5Y CAGR: +47.4%
Net Debt
-$194M -58.8% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$284M$85M$231M$125M$197M
Short-Term Investments$0$257M$136M$407M$244M
Cash & ST Investments$284M$342M$366M$532M$441M
Net Receivables$0$0$0$14M$27M
Inventory$0$0$0$3M$6M
Other Current Assets$1M$1M$2M$4M$11M
Total Current Assets$289M$348M$375M$562M$485M
Property, Plant & Equip.$284K$719K$560K$5M$4M
Goodwill & Intangibles$0$0$0$16M$18M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$169K$469K$214K$121K$230K
Total Non-Current Assets$453K$1M$774K$20M$23M
Total Assets$290M$349M$376M$583M$508M
— Liabilities —
Accounts Payable$2M$260K$3M$3M$4M
Short-Term Debt$204K$405K$408K$10K$174K
Deferred Revenue$0$0$0$2M$2M
Other Current Liabilities$104K$10M$17M$55M$55M
Total Current Liabilities$9M$17M$30M$73M$61M
Long-Term Debt$0$0$0$0$3M
Other Non-Current Liab.$0$0$0$761K$4M
Total Non-Current Liabilities$16K$408K$0$7M$6M
Total Liabilities$9M$17M$30M$80M$67M
— Equity —
Common Stock$6K$7K$9K$10K$10K
Retained Earnings-$127M-$270M-$459M-$554M-$661M
Accumulated OCI$0-$71K$9K$84K$65K
Total Stockholders Equity$281M$332M$347M$503M$441M
Total Liabilities & Equity$290M$349M$376M$583M$508M
— Key Metrics —
Total Debt$220K$813K$408K$3M$3M
Net Debt-$284M-$84M-$230M-$122M-$194M
Total Investments$0$257M$136M$407M$244M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms